Friday, March 22, 2019

Turning Point Therapeutics Files For IPO

San Diego-based Turning Point Therapeutics, a venture-backed biopharmaceuticals startup which is developing small molecule drugs for treating lung cancer and solid tumors, has filed for an IPO. According to a regulatory filing, the company is looking to raise up to $100M in its IPO on the Nasdaq Global Market as TPTX. The IPO is being underwritten

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.